Market Research Logo

EpiCast Report: Systemic Lupus Erythematosus (SLE) - Epidemiology Forecast to 2025

EpiCast Report: Systemic Lupus Erythematosus (SLE) - Epidemiology Forecast to 2025

Summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of multifactorial origin that can affect any organ or organ system, resulting in a broad spectrum of clinical manifestations ranging from dermatological involvement to multi-organ failure with episodes of relapses and remissions. Because of its dynamic nature, this disease has an unpredictable natural course leading to high rates of morbidity and even death. The incidence and prevalence of SLE varies globally and the variation is attributed to a combination of elements such as the characteristics of the population studied, sex, ethnicity, geographical locations, occupational factors, familial traits, time of study, and the diagnostic criteria used.
In 2015, the 7MM had 475,698 diagnosed prevalent cases of SLE, for all ages, men and women combined. The US accounted for approximately 53% of the diagnosed prevalent cases (253,215) in the 7MM. GlobalData epidemiologists forecast that there will be 498,420 diagnosed prevalent cases of SLE in the 7MM by 2025, with an Annual Growth Rate (AGR) of 0.48% during the forecast period. The diagnosed prevalent cases of SLE are projected to increase in all markets, except for Germany and Japan, where there were slight decreases during the forecast period. The increase in the prevalent cases of SLE in the US and the UK are attributed to a forecast increase in SLE prevalence over time and changes in the underlying population. GlobalData epidemiologists held the prevalence constant for the remaining markets; thus any changes observed in the remaining markets are attributed to changes in the population.

GlobalData epidemiologists utilized data from country-specific studies published in peer-reviewed journals and governmental documents to provide the age- and sex-specific prevalence of diagnosed SLE in the respective markets. The forecast methodology was consistent across all of the 7MM to allow for a meaningful comparison among them.

Scope

  • The Systemic Lupus Erythematosus (SLE) EpiCast Report provides an overview of the risk factors, comorbidities, and global and historical trends of SLE in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed prevalent cases of SLE (as per the 1997 revised American College of Rheumatology classification) segmented by sex, age, and severity. This report also provides an epidemiological forecast of the diagnosed prevalent cases of lupus nephritis (LN) among SLE patients for the 7MM, segmented into both 1995 WHO classifications (1985 for Japan) and 2003 ISN/RPS classifications.
  • The SLE epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The SLE EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global SLE market.
  • Quantify patient populations in the global SLE market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SLE therapeutics in each of the markets covered.
  • Identify the percentage of diagnosed prevalent cases of SLE by severity.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global Trends
2.3.1 SLE and LN Prevalence
2.3.2 LN Classification
2.4 Forecast Methodology
2.4.1 Sources Used Tables
2.4.2 Forecast Assumptions and Methods
2.4.3 Sources Not Used
2.5 Epidemiological Forecast for SLE (2015-2025)
2.5.1 Diagnosed Prevalent Cases of SLE
2.5.2 Age-Specific Diagnosed Prevalent Cases of SLE
2.5.3 Sex-Specific Prevalent Cases of SLE
2.5.4 Age-Standardized Diagnosed Prevalence of SLE
2.5.5 Diagnosed Prevalent Cases SLE Segmented by Severity
2.5.6 Prevalent Cases of LN
2.5.7 Diagnosed Prevalent Cases of LN Segmented by Class
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 Primary Research - Prescriber Survey
3.3 About the Authors
3.3.1 Epidemiologists
3.3.2 Reviewers
3.3.3 Global Director of Therapy Analysis and Epidemiology
3.4 About GlobalData
3.5 About EpiCast
3.6 Disclaimer
1.1 List of Tables
Table 1: The 1982 Revised ACR Criteria For Classification of Systemic Lupus Erythematosus
Table 2: WHO and ISN/RPS Classification Systems for LN
Table 3: Risk Factors for SLE
Table 4: 7MM, Sources Used for Diagnosed Prevalence of SLE
Table 5: 7MM, Sources Used for Diagnosed Prevalence of Mild and Moderate/Severe SLE
Table 6: 7MM, Sources Used for Diagnosed Prevalence of LN
Table 7: 7MM, Sources Used for Diagnosed Prevalent Cases of LN Classified by the WHO Classification
Table 8: 7MM, Sources Used for Classifying LN by the ISN/RPS Classification
Table 9: 7MM, Sources Not Used in Epidemiological Analysis of SLE
Table 10: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Both Sexes, N, Select Years 2015-2025
Table 11: 7MM, Age-Specific Diagnosed Prevalent Cases of SLE, Both Sexes, N, Row (%), 2015
Table 12: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, By Sex, N, Row (%), 2015
Table 13: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Men and Women, By Severity, N, Row (%), 2015
Table 14: 7MM, Diagnosed Prevalent Cases of LN, All Ages, Both Sexes, N, Select Years 2015-2025
Table 15: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by WHO Class, Row (%), 2015
Table 16: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by ISN/RPS Class, Row (%), 2015
Table 17: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country
1.2 List of Figures
Figure 1: SLE Forecast Case Flow Map
Figure 2: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Both Sexes, N, 2015-2025
Figure 3: 7MM, Diagnosed Prevalent Cases of SLE, by Age, Both Sexes, N, 2015
Figure 4: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, By Sex, N, 2015
Figure 5: 7MM, Age-Standardized Diagnosed Prevalence (Cases per 100,000 Population) of SLE, All Ages, by Sex, 2015
Figure 6: 7MM, Diagnosed Prevalent Cases of SLE, All Ages, Men and Women, By Severity, N, 2015
Figure 7: 7MM, Diagnosed Prevalent Cases of LN, All Ages, Both Sexes, N, 2015‒2025
Figure 8: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by WHO Class, 2015
Figure 9: 7MM, Diagnosed Prevalent Cases of LN, Both Sexes, All Ages, by ISN/RPS Class, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report